SL
TSHA icon

Siren LLC’s Taysha Gene Therapies TSHA Stock Holding History

Siren LLC’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$67.1M Buy
9,846,579
+1,016,666
+12% +$6.02M 1.36% 23
2026
Q1 		$39.5M Sell
8,829,913
-1,300,000
-13% -$6.04M 1.09% 27
2025
Q4 		$55.7M Sell
10,129,913
-884,824
-8% -$4.3M 1.66% 20
2025
Q3 		$36M Hold
11,014,737
– – 1.41% 23
2025
Q2 		$25.4M Buy
11,014,737
+4,500,000
+69% +$9.78M 1.32% 23
2025
Q1 		$9.06M Sell
6,514,737
-87,738
-1% -$147K 0.51% 41
2024
Q4 		$11.4M Buy
6,602,475
+1,722,600
+35% +$3.57M 0.5% 44
2024
Q3 		$9.81M Buy
+4,879,875
New +$10.7M 0.49% 45

Other funds holding TSHA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Siren LLC's TSHA Position: Q2 2026 in Review

Siren LLC increased its Taysha Gene Therapies (TSHA) stake by 12% in Q2 2026, buying an estimated $6.02M and bringing the position to 9,846,579 shares worth $67.1M. The position accounts for 1.36% of the portfolio, ranked #23.

Siren LLC first reported a position in TSHA in Q3 2024 and has held it in 8 quarters since. 209 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • Siren LLC held 9,846,579 shares of Taysha Gene Therapies worth $67.1M as of Q2 2026.
  • Siren LLC bought 1,016,666 Taysha Gene Therapies shares in Q2 2026, an estimated $6.02M.
  • Taysha Gene Therapies made up 1.36% of Siren LLC's portfolio in Q2 2026, its #23 holding.
  • Siren LLC first reported a position in Taysha Gene Therapies in Q3 2024 and has held it in 8 quarters since.
  • 209 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Siren LLC's 13F filing for Q2 2026, filed 13 Aug 2026.